StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
16
Publishing Date
2022 - 09 - 22
1
2022 - 01 - 13
1
2021 - 12 - 17
1
2021 - 12 - 09
1
2021 - 11 - 17
1
2021 - 11 - 12
1
2021 - 07 - 28
1
2021 - 05 - 26
1
2021 - 05 - 21
2
2021 - 05 - 07
1
2021 - 04 - 21
1
2021 - 04 - 15
1
2021 - 03 - 26
1
2021 - 03 - 11
1
2021 - 01 - 12
1
Sector
Health technology
16
Tags
Alliances
3
Antibody
7
Authorization
3
Authorized
3
Biotech
40
Biotech-bay
16
Biotechnology
4
Business
4
Care
4
Chronic hepatitis b
9
Collaboration
4
Conference
10
Covid
18
Covid-19
4
Ema
4
Emergency use authorization
4
Fda
3
Financial
13
Financial results
5
Global
5
Health
3
Hepatitis
26
Hiv
3
Infection
3
Infections
5
Influenza
6
Injection
4
Iot
29
Liver
10
Market
4
Meeting
5
Merge
3
N/a
89
Ongoing
4
People
4
Phase 1
4
Phase 2
10
Phase 3
4
Platform
3
Positive
6
Potential
5
Pre-clinical
5
Preclinical
5
Presentation
4
Report
8
Research
5
Results
23
Risk
3
Sars-cov-2
8
Technology
27
Therapeutics
3
Treatment
16
Trial
17
Update
14
Vaccine
9
Vir-2218
5
Vir-2482
3
Vir-3434
3
Virus
4
Year
3
Entities
Alnylam pharmaceuticals, inc.
2
Eli lilly and company
6
Glaxosmithkline plc
13
Sanofi
12
Vbi vaccines, inc.
1
Vir biotechnology, inc.
16
Xencor, inc.
2
Symbols
ABBV
117
ABT
57
ADMP
19
ALNY
38
ALPMF
51
ALPMY
51
AMGN
46
ARQT
24
ARWR
22
AZN
46
AZNCF
38
BHC
35
BIIB
41
BMY
93
BSX
21
BTAI
19
BWAY
39
CHRS
28
CNSP
26
ECL
47
FBIO
27
FNCTF
84
GILD
50
GLAXF
73
GSK
98
HOTH
24
HZNP
19
INCY
77
IONS
19
JNJ
198
KPTI
27
LLY
175
MBRX
28
MDT
44
MMM
20
MNOV
24
MRK
63
NRXP
19
NTLA
31
NVO
34
NVS
138
NVSEF
114
PFE
74
PHG
20
PRGO
19
RARE
25
REGN
58
RETA
28
RGNX
25
SNY
281
SNYNF
233
SRNE
37
TAK
51
TEVJF
76
TGTX
24
TNXP
29
VRCA
23
VRTX
27
VTRS
45
XYL
35
Exchanges
Nasdaq
16
Nyse
13
Crawled Date
2022 - 09 - 22
1
2022 - 01 - 13
1
2021 - 12 - 17
1
2021 - 12 - 09
1
2021 - 11 - 17
1
2021 - 11 - 12
1
2021 - 07 - 28
1
2021 - 05 - 26
1
2021 - 05 - 21
2
2021 - 05 - 07
1
2021 - 04 - 21
1
2021 - 04 - 15
1
2021 - 03 - 26
1
2021 - 03 - 11
1
2021 - 01 - 12
1
Crawled Time
02:00
1
08:03
1
12:00
3
12:15
1
13:00
2
13:20
1
13:30
1
14:00
3
14:30
1
15:30
1
23:00
1
Source
www.biospace.com
6
www.globenewswire.com
9
www.vbivaccines.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Treatment
symbols :
Vir
save search
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
Published:
2022-09-22
(Crawled : 13:20)
- biospace.com/
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-57.01%
|
O:
-1.55%
H:
2.68%
C:
1.2%
ALNY
|
$143.8
-1.55%
-1.58%
400K
|
Health Technology
|
-30.33%
|
O:
-0.53%
H:
0.0%
C:
-1.26%
vir-2218
treatment
hepatitis
vir-3434
virus
trial
infection
phase 2
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
Published:
2022-01-13
(Crawled : 15:30)
- biospace.com/
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-10.41%
|
O:
0.0%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
-9.84%
|
O:
0.29%
H:
0.0%
C:
0.0%
XNCR
|
$19.02
3.54%
3.57%
760K
|
Health Technology
|
-47.82%
|
O:
0.38%
H:
1.12%
C:
-1.31%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-79.91%
|
O:
1.05%
H:
1.98%
C:
-6.88%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-7.69%
|
O:
-0.74%
H:
0.0%
C:
0.0%
covid-19
treatment
fda
application
covid
authorization
merge
emergency use authorization
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
Published:
2021-12-17
(Crawled : 13:30)
- globenewswire.com
GLAXF
|
News
|
$19.54
-3.77%
-14.18%
170
|
Health Technology
|
-6.37%
|
O:
2.36%
H:
0.46%
C:
0.46%
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-2.42%
|
O:
-0.48%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
-5.48%
|
O:
0.86%
H:
0.0%
C:
0.0%
XNCR
|
$19.02
3.54%
3.57%
760K
|
Health Technology
|
-48.01%
|
O:
-0.45%
H:
0.0%
C:
0.0%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-85.52%
|
O:
-4.59%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-3.66%
|
O:
0.22%
H:
0.0%
C:
0.0%
covid-19
treatment
europe
granted
covid
authorization
grant
Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection
Published:
2021-12-09
(Crawled : 14:30)
- biospace.com/
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-80.81%
|
O:
-1.69%
H:
6.48%
C:
2.62%
vir-2218
treatment
phase 2
hepatitis
technology
trial
biotech
infection
iot
infections
chronic hepatitis b
nivolumab
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
Published:
2021-11-17
(Crawled : 12:00)
- globenewswire.com
GLAXF
|
News
|
$19.54
-3.77%
-14.18%
170
|
Health Technology
|
-3.92%
|
O:
1.43%
H:
2.31%
C:
2.27%
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
-3.56%
|
O:
-0.28%
H:
0.0%
C:
0.0%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-75.38%
|
O:
9.97%
H:
4.0%
C:
-6.28%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-7.35%
|
O:
-0.06%
H:
0.0%
C:
0.0%
covid
treatment
biotech
technology
iot
covid-19
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Published:
2021-11-12
(Crawled : 13:00)
- biospace.com/
GLAXF
|
News
|
$19.54
-3.77%
-14.18%
170
|
Health Technology
|
-5.31%
|
O:
1.8%
H:
0.0%
C:
-0.31%
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
-5.15%
|
O:
0.93%
H:
0.0%
C:
0.0%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-75.19%
|
O:
4.66%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-7.82%
|
O:
-0.66%
H:
0.0%
C:
0.0%
covid
treatment
phase 3
trial
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
Published:
2021-07-28
(Crawled : 12:00)
- biospace.com/
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
3.39%
|
O:
-1.06%
H:
1.31%
C:
1.02%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-77.94%
|
O:
1.54%
H:
4.68%
C:
0.14%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-8.05%
|
O:
-0.5%
H:
1.7%
C:
1.4%
covid
treatment
europe
biotech
technology
iot
covid-19
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
Published:
2021-05-26
(Crawled : 23:00)
- globenewswire.com
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
5.55%
|
O:
-0.8%
H:
0.69%
C:
0.23%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
274.25%
|
O:
-0.17%
H:
0.36%
C:
-0.72%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-82.43%
|
O:
4.2%
H:
0.3%
C:
-9.4%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-11.99%
|
O:
-0.5%
H:
0.32%
C:
-1.27%
covid
treatment
fda
risk
biotech
technology
iot
merge
authorized
emergency use authorization
CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published:
2021-05-21
(Crawled : 14:00)
- globenewswire.com
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
4.69%
|
O:
-0.26%
H:
0.26%
C:
-0.21%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
276.99%
|
O:
0.24%
H:
0.96%
C:
-0.06%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-82.19%
|
O:
1.75%
H:
0.13%
C:
-1.44%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-12.2%
|
O:
-0.43%
H:
0.2%
C:
0.02%
covid
treatment
positive
biotech
technology
iot
ema
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published:
2021-05-21
(Crawled : 12:15)
- globenewswire.com
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
4.69%
|
O:
-0.26%
H:
0.26%
C:
-0.21%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
276.99%
|
O:
0.24%
H:
0.96%
C:
-0.06%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-82.19%
|
O:
1.75%
H:
0.13%
C:
-1.44%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-12.2%
|
O:
-0.43%
H:
0.2%
C:
0.02%
covid
treatment
positive
biotech
technology
iot
ema
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
Published:
2021-05-07
(Crawled : 14:00)
- biospace.com/
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
7.78%
|
O:
0.5%
H:
0.84%
C:
0.66%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
287.96%
|
O:
0.48%
H:
0.74%
C:
0.31%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-80.68%
|
O:
3.24%
H:
2.94%
C:
0.02%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-6.99%
|
O:
0.92%
H:
0.88%
C:
0.66%
covid
treatment
biotech
technology
iot
ema
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Published:
2021-04-21
(Crawled : 12:00)
- vbivaccines.com
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-83.41%
|
O:
-1.09%
H:
0.38%
C:
0.04%
VBIV
|
$0.59
-3.04%
-3.26%
130K
|
Health Technology
|
-77.39%
|
O:
0.0%
H:
7.66%
C:
7.66%
ALNY
|
$143.8
-1.55%
-1.58%
400K
|
Health Technology
|
5.71%
|
O:
0.67%
H:
1.12%
C:
0.43%
treatment
phase 2
hepatitis
vbi-2601
biotech
vaccine
technology
iot
brii-835
trial
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
Published:
2021-04-15
(Crawled : 14:00)
- globenewswire.com
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
13.09%
|
O:
4.23%
H:
1.59%
C:
0.08%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-82.35%
|
O:
0.37%
H:
2.8%
C:
-1.49%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-5.56%
|
O:
0.76%
H:
0.61%
C:
0.14%
covid
treatment
antibody
biotech
technology
iot
ema
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
Published:
2021-03-26
(Crawled : 13:00)
- globenewswire.com
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
13.28%
|
O:
-0.28%
H:
2.0%
C:
1.95%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
310.84%
|
O:
0.52%
H:
1.01%
C:
0.68%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-84.74%
|
O:
1.27%
H:
1.56%
C:
-3.45%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-3.53%
|
O:
-0.31%
H:
1.33%
C:
1.22%
covid
treatment
fda
biotech
technology
iot
merge
submission
authorized
emergency use authorization
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
Published:
2021-03-11
(Crawled : 02:00)
- globenewswire.com
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
14.78%
|
O:
-0.67%
H:
0.96%
C:
0.54%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
266.13%
|
O:
0.52%
H:
0.36%
C:
-0.63%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-82.83%
|
O:
44.57%
H:
0.75%
C:
-8.66%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-1.05%
|
O:
-0.31%
H:
0.63%
C:
0.08%
covid
treatment
risk
biotech
iot
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
Published:
2021-01-12
(Crawled : 08:03)
- globenewswire.com
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
7.72%
|
O:
-0.29%
H:
0.21%
C:
-0.95%
VIR
|
$8.04
-1.11%
-1.12%
770K
|
Health Technology
|
-71.55%
|
O:
1.91%
H:
16.28%
C:
11.28%
covid
biotech
treatment
Gainers vs Losers
61%
39%
Top 10 Gainers
CSSE
4
|
$0.4253
179.25%
64.77%
210M
|
Consumer Services
BOF
|
$2.08
77.78%
41.21%
110M
|
ILAG
|
$0.54
12.27%
40.62%
3.7M
|
LICN
|
$0.999
78.39%
40.49%
15M
|
AMST
|
$3.4
70.0%
39.58%
70M
|
Technology Services
MTC
|
$3.6
60.71%
38.04%
9.1M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.458
14.5%
30.92%
91K
|
Health Services
WHLM
|
$6.25
35.87%
28.46%
700K
|
Commercial Services
MULN
|
News
|
$3.77
38.1%
27.78%
13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.